

# ACORN CAPITAL INVESTMENT FUND

INVESTMENT UPDATE  
JUNE 2025



## Acorn Capital Investment Fund Limited ACN 167 595 897

### Net Tangible Asset Per Ordinary Share


as at 30 June 2025 (all figures unaudited)

NTA before all taxes	1.1143
NTA after taxes and before taxes on unrealised gains	1.1230
NTA after taxes including taxes on unrealised gains	1.1091

ASX Code	ACQ
Date of Listing	1 May 2014
Shares on Issue	89,599,002
Share Price	\$0.76
Market Cap \$m	\$68.1m
Number of Stocks	77
Dividends	5.5c <sup>A</sup>
Dividend Yield	7.2%*

<sup>A</sup> Ordinary over the past 12 months  
\* Implied on share price

### Investment Split




### Top 10 Stocks as at 30 June 2025

Company	Weight
Aroa Biosurgery	3.3%
Superloop	3.2%
Meeka Metals	3.1%
Elenium Automation (UL)	2.9%
Fremantle Commercial Diving (UL)	2.9%
Padua Financial (UL)	2.9%
Boss Energy	2.8%
EROAD	2.8%
Pantoro	2.7%
Dexus Convenience Retail REIT	2.3%
<b>Total</b>	<b>28.8%</b>

UL = Unlisted investment

### Ratings\*

Lonsec "Recommended"



### Performance as at 30 June 2025 (all figures unaudited)

	1 month %	3 month %	1 year %	3 years % p.a.	5 years % p.a.	Since incept. % p.a.
ACQ <sup>1</sup>	4.6	13.4	15.1	7.3	9.3	8.4
S&P/ASX Small Ords Acc Index <sup>2</sup>	0.8	8.6	12.3	10.0	7.4	6.8

<sup>1</sup> Calculated as the movement in NTA pre tax but post fees and operating costs and using closing bid price. The calculation includes dividends paid and payable but has not been grossed-up for franking credits received by shareholders. All figures are unaudited, and unlisted valuations are prepared by Acorn Capital in accordance with ACQ Board approved policies. <sup>2</sup> The stated benchmark for the strategy. Please note that there is a difference in underlying investment universe and over shorter time periods, deviations in returns (both positive and negative) are expected. Please see page 2 for further details on benchmarks and investment universe.


### Acorn Capital - Investment Update

"Global markets showed resilience in June, despite geopolitical volatility. The S&P/ASX Small Ordinaries closed +0.8% lagging the ASX 200 (+1.4%), which reached an all-time high during the month. Industry sector performance in the benchmark was mixed for the month, with Energy (+10.7%), Industrials – Capital Goods (+8.8%), and Financials – ex REITS (+7.0%) leading the gains. Resources (-6.3%), Healthcare (-2.5%), and Consumer Discretionary (-2.1%) were the worst performing sectors.

The portfolio returned 4.6% for the month, outperforming the benchmark by 3.8%. Significant contributors included Amplia Therapeutics (+278.8%), which surged after announcing two complete responses in its ACCENT clinical trial for advanced pancreatic cancer, an extremely rare outcome. ZIP Co (+60.9%) also performed strongly, driven by a robust FY25 trading update that upgraded its full-year cash EBITDA guidance to at least \$160 million, up from \$153 million, supported by strong performance in its U.S. operations where transaction volume grew over 40% year-on-year. Golden Horse Minerals (-10.1%) detracted from performance due to a significant capital raising to fund expanded drilling at its Hopes Hill gold project."


### ACQ Investment Manager – Acorn Capital Limited

### Growth \$10K




\*Total shareholder return assuming dividends reinvested, includes special dividends

### Market Cap Bands



### Sector Exposures



**Expanded Performance** as at 30 June 2025 (all figures unaudited)

	1 mth	3 mth	1 year	3 years p.a.	5 years p.a.	Since incept. p.a.
ACQ (Pre fees, tax and operating costs) <sup>2</sup>	5.1	14.0	17.9	9.0	12.0	11.1
S&P/ASX Small Ords Acc Index <sup>3</sup>	0.8	8.6	12.3	10.0	7.4	6.8
Acorn Capital / SIRCA Microcap Acc. Index <sup>4</sup>	2.4	5.9	12.7	6.9	9.3	7.0

<sup>1</sup> Refer disclaimer page 1. <sup>2</sup> Return represents the pre fee, tax and operating cost performance of the underlying portfolio based on last prices, excluding fees and other accounting adjustments reflected in the calculation of Net Tangible Assets (NTA). This return is calculated by Acorn Capital and is unaudited <sup>3</sup> Source: Factset <sup>4</sup> Acorn Capital / SIRCA Microcap Accumulation Index data is verified 3 months in arrears by SIRCA ('Securities Industry Research Centre of Asia-Pacific').

**Indices Characteristics** <sup>5</sup>

	S&P/ASX Small Ordinaries Acc Index	Acorn Capital / SIRCA Microcap Acc. Index
Companies (by number)	199	>1400
Universe (by size)	ASX 101 – 300	ASX ex-250
Total Market Cap (\$M)	277,895	157,996
Median Market Cap (\$M)	1,179	26
Exposure to Developing Companies <sup>5,6</sup>	17.6%	43.0%
Crossover of holdings in ACQ <sup>5,7</sup>	23%	49%

<sup>5</sup> As at 30 June 2025 <sup>6</sup> Number of stocks, developing companies defined as those with revenues <10 of their market cap <sup>7</sup> the total portfolio weight of listed stocks (excludes unlisted and cash), included in the index.

**ACQ Objective**

The Objective is to create a diversified portfolio of listed microcap companies and then to invest opportunistically in unlisted entities that offer better relative value. The performance objective for ACQ is to outperform the S&P/ASX Small Ordinaries Accumulation Index over the medium to long term.

**Dividend Intention**

Acorn Capital Investment Fund Limited intends to pay annual dividends targeting at least 5% of closing post-tax NTA for each financial year, franked to the highest extent possible and without the Company incurring a liability.

Where the Company accumulates franking credits that the Board determines are in excess to its requirements it is the intent to distribute those excess credits by way of special dividends. This is subject to the Company having sufficient profit and cash flow to make such payments.

**Investment Philosophy**

The investment philosophy is based on a belief that there are pricing inefficiencies amongst emerging or microcap companies due to a lack of readily available external research conducted on such entities.

Acorn Capital believes that through a research driven investment process the pricing inefficiencies that exist in both listed microcaps and unlisted microcaps can be exploited to earn returns superior to those available in the broader market.

Unlisted microcap opportunities must be of better relative value on a risk-adjusted basis to displace existing listed portfolio investments in the corresponding sector.

**Investment Strategy**

- Research-driven stock selection
- Economic sector diversified
- Style agnostic
- Long term investor
- Create diversified portfolios to reduce volatility

**Investment Manager profile**

Acorn Capital was established in 1998 as a specialist investment manager in emerging Australian companies.

Acorn Capital distinguishes itself through its relatively large research and investment team with expertise across all industries as well as its provision of expansion capital to developing companies.

Through its strategies Acorn Capital can provide Investors with efficient off-index exposure to both public and private emerging companies.

\*The rating issued 10/2023 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved.

